The clinical and prognostic significance of FOXN3 downregulation in acute myeloid leukaemia

Autor: Yue Wang, Yan Li, Rui Zhang, Jinjing Zhang, Wenbin Mo
Rok vydání: 2019
Předmět:
Oncology
Adult
Male
medicine.medical_specialty
Multivariate analysis
Adolescent
diagnosis
Clinical Biochemistry
chemotherapy response
FOXN3
Down-Regulation
Cell Cycle Proteins
030204 cardiovascular system & hematology
Disease-Free Survival
03 medical and health sciences
0302 clinical medicine
Downregulation and upregulation
Internal medicine
White blood cell
hemic and lymphatic diseases
medicine
Humans
Clinical significance
acute myeloid leukaemia
Aged
Aged
80 and over
business.industry
Gene Expression Regulation
Leukemic
Biochemistry (medical)
Complete remission
Forkhead Transcription Factors
Hematology
General Medicine
Original Articles
Middle Aged
Neoplasm Proteins
Survival Rate
Leukemia
Myeloid
Acute
medicine.anatomical_structure
Biomarker (medicine)
Female
Original Article
prognosis
Myeloid leukaemia
business
Chemotherapy response
030215 immunology
Follow-Up Studies
Zdroj: International Journal of Laboratory Hematology
ISSN: 1751-553X
Popis: Introduction The expression of forkhead box N3 (FOXN3), also known as checkpoint suppressor 1 (CHES1), is reduced in many types of tumours. However, the clinical significance of FOXN3 and its potential role in acute myeloid leukaemia (AML) remain largely unknown. Methods A total of 117 de novo AML patients newly diagnosed between December 2015 and January 2018 were included in this study. The expression of FOXN3 and its clinical significance were analysed in these AML patients. Results The expression of FOXN3 was significantly downregulated in AML. In addition, lower FOXN3 expression was associated with older age and higher white blood cell counts. Moreover, a close correlation was observed between lower FOXN3 expression and a lower complete remission (CR) rate and shorter overall survival (OS), which was further analysed by multivariate analysis. Conclusion These data suggest that FOXN3 is a novel biomarker in AML and that lower FOXN3 expression predicts poor chemotherapy response and prognosis in AML.
Databáze: OpenAIRE
Externí odkaz: